Effects of denosumab on the treatment of osteoporosis and inhibition of bone erosion in rheumatoid arthritis

Effects of denosumab on the treatment of osteoporosis and inhibition of bone erosion in rheumatoid arthritis - Evaluation of the Therapeutic Effect of Denosumab on Rheumatoid Arthritis and Osteoporosis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000042107

Enrollment

200

Registered

2020-10-14

Start date

2021-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Meet the diagnosis of rheumatoid arthritis and osteoporosis

Exclusion criteria

Exclusion criteria: Use of parathyroid hormones drugs History of bone metabolic disease hypocalcemia

Design outcomes

Primary

Measure	Time frame
Evaluation of Bone Mineral Density at week 52	—

Secondary

Measure	Time frame
Evaluation of Bone Erosion at week 52	—

Countries

Japan

Contacts

Public ContactYu Mori

Tohoku University Graduate School of Medicine Orthopedic Surgery

yu-mori@med.tohoku.ac.jp0227177245

Outcome results